Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Open accessThe DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Abstract
Osteolytic bone disease is the hallmark of multiple myeloma, which deteriorates the quality of life of myeloma patients, and it affects dramatically their morbidity and mortality. The basis of the pathogenesis of myeloma-related bone disease is the uncoupling of the bone-remodeling process. The interaction between myeloma cells and the bone microenvironment ultimately leads to the activation of osteoclasts and suppression of osteoblasts, resulting in bone loss. Several intracellular and intercellular signaling cascades, including RANK/RANKL/OPG, Notch, Wnt, and numerous chemokines and interleukins are implicated in this complex process. During the last years, osteocytes have emerged as key regulators of bone loss in myeloma through direct interactions with the myeloma cells. The myeloma-induced crosstalk among the molecular pathways establishes a positive feedback that sustains myeloma cell survival and continuous bone destruction, even when a plateau phase of the disease has been achieved. Targeted therapies, based on the better knowledge of the biology, constitute a promising approach in the management of myeloma-related bone disease and several novel agents are currently under investigation. Herein, we provide an insight into the underlying pathogenesis of bone disease and discuss possible directions for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Multiple myeloma patients are at higher risk for bone fractures due to malignant plasma cells over-activating OCs and suppressing OBs [78].”
From Osteoimmunology of Fracture Healing. (2024) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2452 · Cited by 1,778
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
Lam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11176 · Cited by 1,440
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling
Mao, B., Wu, W., Davidson, G., Marhold, J., Li, M., Mechler, B. M., Delius, H., Hoppe, D., Stannek, P., Walter, C., et al. (2002) · Nature · doi:10.1038/nature756 · Cited by 1,038
Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis
Zhao, C., Irie, N., Takada, Y., Shimoda, K., Miyamoto, T., Nishiwaki, T., Suda, T., & Matsuo, K. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.012 · Cited by 777
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myeloma
Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U. K., Pitsillides, C. M., Spencer, J. A., Kimlinger, T., Ghobrial, J. M., Jia, X., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035857 · Cited by 478
Terpos, E., Szydlo, R., Apperley, J. F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J. M., & Rahemtulla, A. (2003) · Blood · doi:10.1182/blood-2003-02-0380 · Cited by 410
Self-citation
Cited by
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00529-7 · Cited by 337
Self-citationMetastatic bone disease: Pathogenesis and therapeutic options
D'Oronzo, S., Coleman, R., Brown, J., & Silvestris, F. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2018.10.004 · Cited by 255
Invasion and metastasis in cancer: molecular insights and therapeutic targets
Li, Y., Liu, F., Cai, Q., Deng, L., Ouyang, Q., Zhang, X. H.-F., & Zheng, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02148-4 · Cited by 244
Terpos, E., Zamagni, E., Lentzsch, S., Drake, M. T., García-Sanz, R., Abildgaard, N., Ntanasis-Stathopoulos, I., Schjesvold, F., de la Rubia, J., Kyriakou, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30559-3 · Cited by 212
Self-citation
Metadata
- Authors
- Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Terpos, Evangelos
- Venue
- Blood Cancer Journal
- Published
- 2018-01-12
- Volume
- 8
- Issue
- 1
- Pages
- 7-7
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC5802524
- OpenAlex
- W2783965560
- Cited by
- 354
- References
- 101
- Citations by year
- 2026: 38 · 2025: 44 · 2024: 42 · 2023: 49 · 2022: 32 · 2021: 57 · 2020: 50 · 2019: 28 · 2018: 14
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- multiple myeloma, osteolytic bone disease, bone remodeling, osteoclast activation, RANK/RANKL/OPG signaling, Notch signaling, Wnt signaling, chemokines, interleukins, osteocytes, targeted therapy
- MeSH terms
- Humans, Multiple Myeloma, Neoplasm Proteins, Osteoblasts, Osteoclasts, Osteolysis, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pathogenesis of bone disease in multiple myeloma: from bench to bedside. https://app.cochat.ai/papers/10.1038/s41408-017-0037-4
- The paper
- Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A. (2018). Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer Journal. https://doi.org/10.1038/s41408-017-0037-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.